Source - RNS
RNS Number : 9373L
Cyprotex PLC
06 October 2016

Cyprotex PLC
("Cyprotex" or "the Company")
Conversion of Loan Notes & Total Voting Rights

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that it has issued 40,702 new ordinary shares of 1p each ("new Ordinary Shares") pursuant to the conversion of Convertible Loan Notes.

The issue of these new Ordinary Shares is subject to the new Ordinary Shares being admitted to trading on AIM, application for which has been made. Trading in the new Ordinary Shares, which will rank pari passu in all respects with the existing ordinary shares, is expected to commence on 12 October 2016.

Total Voting Rights

Following the issue of the 40,702 new Ordinary Shares on 12 October 2016, the Company will have a total of 22,509,042 Ordinary Shares in issue and one voting right per Ordinary Share.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure and Transparency Rules.

For further information:


Cyprotex PLC

Tel: +44 (0) 1625 505 100

Dr Anthony Baxter, Chief Executive Officer

John Dootson, Chief Financial Officer

Mark Warburton, Chief Operating Officer and Legal Counsel

[email protected]

N+1 Singer (Nomad & Broker)

Tel: +44 (0)20 7496 3000

Shaun Dobson

Jen Boorer


[email protected]

[email protected]

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX).  It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US.  The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit



This information is provided by RNS
The company news service from the London Stock Exchange